Restoring old revision of "Q35591518"

Jump to navigation Jump to search

Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to a username, among other benefits.

Latest revision
Your text
label / enlabel / en
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications.
label / astlabel / ast
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications
label / nllabel / nl
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications
description / astdescription / ast
artículu científicu espublizáu en 2011
artículu científicu
description / ukdescription / uk
наукова стаття, опублікована в травні 2011
наукова стаття
Property / instance of
 
Property / instance of: review article / rank
Normal rank
 
Property / instance of: review article / reference
 
Property / titleProperty / title
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications (English)
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. (English)
Property / cites work
 
Property / cites work: Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy / rank
Normal rank
 
Property / cites work: Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy / reference
 
Property / cites work
 
Property / cites work: Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation / rank
Normal rank
 
Property / cites work: Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation / reference
 
Property / cites work
 
Property / cites work: Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer / rank
Normal rank
 
Property / cites work: Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer / reference
 
Property / cites work
 
Property / cites work: The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity / rank
Normal rank
 
Property / cites work: The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity / reference
 
Property / cites work
 
Property / cites work: H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3 / rank
Normal rank
 
Property / cites work: H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3 / reference
 
Property / cites work
 
Property / cites work: Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer / rank
Normal rank
 
Property / cites work: Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer / reference
 
Property / cites work
 
Property / cites work: Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. / rank
Normal rank
 
Property / cites work: Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. / reference
 
Property / cites work
 
Property / cites work: Resiliency and vulnerability in the HER2-HER3 tumorigenic driver / rank
Normal rank
 
Property / cites work: Resiliency and vulnerability in the HER2-HER3 tumorigenic driver / reference
 
Property / cites work
 
Property / cites work: An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation / rank
Normal rank
 
Property / cites work: An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation / reference
 
Property / cites work
 
Property / cites work: Differences underlying EGFR and HER2 oncogene addiction / rank
Normal rank
 
Property / cites work: Differences underlying EGFR and HER2 oncogene addiction / reference
 
Property / cites work
 
Property / cites work: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer / rank
Normal rank
 
Property / cites work: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer / reference
 
Property / cites work
 
Property / cites work: Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. / rank
Normal rank
 
Property / cites work: Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. / reference
 
Property / cites work
 
Property / cites work: Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer / rank
Normal rank
 
Property / cites work: Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer / reference
 
Property / cites work
 
Property / cites work: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy / rank
Normal rank
 
Property / cites work: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy / reference
 
Property / cites work
 
Property / cites work: Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. / rank
Normal rank
 
Property / cites work: Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. / reference
 
Property / cites work
 
Property / cites work: Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells / rank
Normal rank
 
Property / cites work: Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells / reference
 
Property / cites work
 
Property / cites work: Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models / rank
Normal rank
 
Property / cites work: Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models / reference
 
Property / cites work
 
Property / cites work: Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. / rank
Normal rank
 
Property / cites work: Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. / reference
 
Property / cites work
 
Property / cites work: An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance / rank
Normal rank
 
Property / cites work: An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance / reference
 
Property / cites work
 
Property / cites work: Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling / rank
Normal rank
 
Property / cites work: Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling / reference
 
Property / cites work
 
Property / cites work: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 / rank
Normal rank
 
Property / cites work: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 / reference
 
Property / cites work
 
Property / cites work: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. / rank
Normal rank
 
Property / cites work: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. / reference
 
Property / cites work
 
Property / cites work: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate / rank
Normal rank
 
Property / cites work: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate / reference
 
Property / cites work
 
Property / cites work: Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. / rank
Normal rank
 
Property / cites work: Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. / reference
 
Property / cites work
 
Property / cites work: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. / rank
Normal rank
 
Property / cites work: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. / reference
 
Property / cites work
 
Property / cites work: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer / rank
Normal rank
 
Property / cites work: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer / reference
 
Property / cites work
 
Property / cites work: A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy / rank
Normal rank
 
Property / cites work: A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy / reference
 
Property / cites work
 
Property / cites work: Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab / rank
Normal rank
 
Property / cites work: Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab / reference
 
Property / cites work
 
Property / cites work: Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells / rank
Normal rank
 
Property / cites work: Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells / reference
 
Property / cites work
 
Property / cites work: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer / rank
Normal rank
 
Property / cites work: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer / reference
 
Property / cites work
 
Property / cites work: Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network / rank
Normal rank
 
Property / cites work: Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network / reference
 
Property / cites work
 
Property / cites work: Targeting HER proteins in cancer therapy and the role of the non-target HER3. / rank
Normal rank
 
Property / cites work: Targeting HER proteins in cancer therapy and the role of the non-target HER3. / reference
 
Property / cites work
 
Property / cites work: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer / rank
Normal rank
 
Property / cites work: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer / reference
 
Property / cites work
 
Property / cites work: The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis / rank
Normal rank
 
Property / cites work: The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis / reference
 
Property / cites work
 
Property / cites work: Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. / rank
Normal rank
 
Property / cites work: Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. / reference
 
Property / cites work
 
Property / cites work: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. / rank
Normal rank
 
Property / cites work: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. / reference
 
Property / cites work
 
Property / cites work: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 / rank
Normal rank
 
Property / cites work: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 / reference
 
Property / cites work
 
Property / cites work: Lapatinib plus capecitabine for HER2-positive advanced breast cancer / rank
Normal rank
 
Property / cites work: Lapatinib plus capecitabine for HER2-positive advanced breast cancer / reference
 
Property / cites work
 
Property / cites work: Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer / rank
Normal rank
 
Property / cites work: Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer / reference
 
Property / cites work
 
Property / cites work: HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors / rank
Normal rank
 
Property / cites work: HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors / reference
 
Property / cites work
 
Property / cites work: Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. / rank
Normal rank
 
Property / cites work: Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. / reference
 
Property / cites work
 
Property / cites work: Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases / rank
Normal rank
 
Property / cites work: Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases / reference
 
Property / cites work
 
Property / cites work: A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer / rank
Normal rank
 
Property / cites work: A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer / reference
 
Property / cites work
 
Property / cites work: Role of exon-16-deleted HER2 in breast carcinomas / rank
Normal rank
 
Property / cites work: Role of exon-16-deleted HER2 in breast carcinomas / reference
 
Property / cites work
 
Property / cites work: Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells / rank
Normal rank
 
Property / cites work: Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells / reference
 
Property / cites work
 
Property / cites work: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer / rank
Normal rank
 
Property / cites work: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer / reference
 
Property / cites work
 
Property / cites work: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma / rank
Normal rank
 
Property / cites work: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma / reference
 
Property / cites work
 
Property / cites work: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. / rank
Normal rank
 
Property / cites work: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. / reference
 
Property / cites work
 
Property / cites work: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain / rank
Normal rank
 
Property / cites work: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain / reference
 
Property / cites work
 
Property / cites work: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib / rank
Normal rank
 
Property / cites work: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib / reference
 
Property / cites work
 
Property / cites work: Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. / rank
Normal rank
 
Property / cites work: Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. / reference
 
Property / cites work
 
Property / cites work: Lung cancer: intragenic ERBB2 kinase mutations in tumours / rank
Normal rank
 
Property / cites work: Lung cancer: intragenic ERBB2 kinase mutations in tumours / reference
 
Property / cites work
 
Property / cites work: Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway / rank
Normal rank
 
Property / cites work: Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway / reference
 
Property / cites work
 
Property / cites work: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. / rank
Normal rank
 
Property / cites work: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. / reference
 
Property / cites work
 
Property / cites work: A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient / rank
Normal rank
 
Property / cites work: A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient / reference
 
Property / cites work
 
Property / cites work: P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. / rank
Normal rank
 
Property / cites work: P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. / reference
 
Property / cites work
 
Property / cites work: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex / rank
Normal rank
 
Property / cites work: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex / reference
 
Property / cites work
 
Property / cites work: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation / rank
Normal rank
 
Property / cites work: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation / reference
 
Property / cites work
 
Property / cites work: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab / rank
Normal rank
 
Property / cites work: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab / reference
 
Property / cites work
 
Property / cites work: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action / rank
Normal rank
 
Property / cites work: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action / reference
 
Property / cites work
 
Property / cites work: Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance / rank
Normal rank
 
Property / cites work: Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance / reference
 
Property / cites work
 
Property / cites work: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer / rank
Normal rank
 
Property / cites work: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer / reference
 
Property / cites work
 
Property / cites work: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification / rank
Normal rank
 
Property / cites work: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification / reference
 
Property / cites work
 
Property / cites work: Untangling the ErbB signalling network / rank
Normal rank
 
Property / cites work: Untangling the ErbB signalling network / reference
 
Property / cites work
 
Property / cites work: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. / rank
Normal rank
 
Property / cites work: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. / reference
 
Property / cites work
 
Property / cites work: ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. / rank
Normal rank
 
Property / cites work: ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. / reference
 
Property / cites work
 
Property / cites work: ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. / rank
Normal rank
 
Property / cites work: ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. / reference
 
Property / cites work
 
Property / cites work: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling / rank
Normal rank
 
Property / cites work: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling / reference
 
Property / cites work
 
Property / cites work: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer / rank
Normal rank
 
Property / cites work: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer / reference
 
Property / cites work
 
Property / cites work: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions / rank
Normal rank
 
Property / cites work: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions / reference
 
Property / cites work
 
Property / cites work: Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3 / rank
Normal rank
 
Property / cites work: Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3 / reference
 
Property / cites work
 
Property / cites work: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas / rank
Normal rank
 
Property / cites work: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas / reference
 
Property / cites work
 
Property / cites work: HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. / rank
Normal rank
 
Property / cites work: HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. / reference
stated in: PubMed Central
reference URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3230295
retrieved: 26 September 2018
Timestamp+2018-09-26T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / cites work
 
Property / cites work: Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer / rank
Normal rank
 
Property / cites work: Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer / reference
stated in: PubMed Central
reference URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3230295
retrieved: 26 September 2018
Timestamp+2018-09-26T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / cites work
 
Property / cites work: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. / rank
Normal rank
 
Property / cites work: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. / reference
stated in: PubMed Central
reference URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3230295
retrieved: 26 September 2018
Timestamp+2018-09-26T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / cites work
 
Property / cites work: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. / rank
Normal rank
 
Property / cites work: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. / reference
stated in: PubMed Central
reference URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3230295
retrieved: 26 September 2018
Timestamp+2018-09-26T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / cites work
 
Property / cites work: Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. / rank
Normal rank
 
Property / cites work: Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. / reference
stated in: PubMed Central
reference URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3230295
retrieved: 26 September 2018
Timestamp+2018-09-26T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / cites work
 
Property / cites work: A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer / rank
Normal rank
 
Property / cites work: A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer / reference
stated in: PubMed Central
reference URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3230295
retrieved: 26 September 2018
Timestamp+2018-09-26T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / cites work
 
Property / cites work: The PIK3CA gene is mutated with high frequency in human breast cancers. / rank
Normal rank
 
Property / cites work: The PIK3CA gene is mutated with high frequency in human breast cancers. / reference
stated in: PubMed Central
reference URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3230295
retrieved: 26 September 2018
Timestamp+2018-09-26T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / cites work
 
Property / cites work: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth / rank
Normal rank
 
Property / cites work: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth / reference
stated in: PubMed Central
reference URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3230295
retrieved: 26 September 2018
Timestamp+2018-09-26T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / cites work
 
Property / cites work: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. / rank
Normal rank
 
Property / cites work: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. / reference
stated in: PubMed Central
reference URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3230295
retrieved: 26 September 2018
Timestamp+2018-09-26T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / cites work
 
Property / cites work: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). / rank
Normal rank
 
Property / cites work: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). / reference
stated in: PubMed Central
reference URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3230295
retrieved: 26 September 2018
Timestamp+2018-09-26T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / cites work
 
Property / cites work: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo / rank
Normal rank
 
Property / cites work: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo / reference
stated in: PubMed Central
reference URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3230295
retrieved: 26 September 2018
Timestamp+2018-09-26T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / cites work
 
Property / cites work: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. / rank
Normal rank
 
Property / cites work: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. / reference
stated in: PubMed Central
reference URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3230295
retrieved: 26 September 2018
Timestamp+2018-09-26T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / cites work
 
Property / cites work: A novel splice variant of HER2 with increased transformation activity / rank
Normal rank
 
Property / cites work: A novel splice variant of HER2 with increased transformation activity / reference
stated in: PubMed Central
reference URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3230295
retrieved: 26 September 2018
Timestamp+2018-09-26T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / cites work
 
Property / cites work: Mutation of the PIK3CA gene in ovarian and breast cancer / rank
Normal rank
 
Property / cites work: Mutation of the PIK3CA gene in ovarian and breast cancer / reference
stated in: PubMed
reference URL: https://pubmed.ncbi.nlm.nih.gov/21307659
retrieved: 12 December 2020
Timestamp+2020-12-12T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0

based on heuristic: inferred from PubMed ID database lookup
 
Property / cites work
 
Property / cites work: Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab / rank
Normal rank
 
Property / cites work: Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab / reference
stated in: PubMed
reference URL: https://pubmed.ncbi.nlm.nih.gov/21307659
retrieved: 12 December 2020
Timestamp+2020-12-12T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0

based on heuristic: inferred from PubMed ID database lookup
 
Property / cites work
 
Property / cites work: Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer / rank
Normal rank
 
Property / cites work: Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer / reference
stated in: PubMed
reference URL: https://pubmed.ncbi.nlm.nih.gov/21307659
retrieved: 12 December 2020
Timestamp+2020-12-12T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0

based on heuristic: inferred from PubMed ID database lookup
 
Property / cites work
 
Property / cites work: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas / rank
Normal rank
 
Property / cites work: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas / reference
stated in: PubMed
reference URL: https://pubmed.ncbi.nlm.nih.gov/21307659
retrieved: 12 December 2020
Timestamp+2020-12-12T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0

based on heuristic: inferred from PubMed ID database lookup
 
Property / ResearchGate publication ID
 
Property / ResearchGate publication ID: 49823407 / rank
Normal rank
 
Property / main subject
 
Property / main subject: antibody / rank
Normal rank
 
Property / main subject: antibody / reference
 
Property / language of work or name
 
Property / language of work or name: English / rank
Normal rank
 
Property / language of work or name: English / reference
 

Cancel
Retrieved from "https://www.wikidata.org/wiki/Q35591518"